Go Pro
→ 3 Ways AI Can Reshape Your Retirement For The Worse (From American Hartford Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$113.78
+2.7%		$89.31
$28.66
▼
$122.21
$12.31B0.451.58 million shs473,265 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.50
+1.7%		$24.70
$16.89
▼
$27.98
$11.23B1.675.65 million shs14.38 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$43.36
-0.4%		$39.45
$12.30
▼
$48.40
$4.71B0.31.18 million shs464,837 shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$257.55
+0.4%		$241.29
$110.26
▼
$265.05
$16.71B0.32948,188 shs344,266 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
0.00%-3.25%+20.56%+116.35%+53.21%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%-16.52%-11.19%+1.79%+32.80%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+13.24%-4.16%+25.93%+243.22%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%+1.46%+5.23%+14.74%+130.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$113.78
+2.7%		$89.31
$28.66
▼
$122.21
$12.31B0.451.58 million shs473,265 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$22.50
+1.7%		$24.70
$16.89
▼
$27.98
$11.23B1.675.65 million shs14.38 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$43.36
-0.4%		$39.45
$12.30
▼
$48.40
$4.71B0.31.18 million shs464,837 shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$257.55
+0.4%		$241.29
$110.26
▼
$265.05
$16.71B0.32948,188 shs344,266 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
0.00%-3.25%+20.56%+116.35%+53.21%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%-16.52%-11.19%+1.79%+32.80%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
0.00%+13.24%-4.16%+25.93%+243.22%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%+1.46%+5.23%+14.74%+130.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.63
Moderate Buy$119.174.73% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$29.0929.32% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$48.7512.43% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.95
Moderate Buy$272.745.90% Upside

Current Analyst Ratings Breakdown

Latest EWTX, JAZZ, ELAN, and CORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$31.00 ➝ $33.00
8/6/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$29.00 ➝ $30.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Buy (B-)
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$287.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$275.00 ➝ $300.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$254.00 ➝ $264.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$315.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$285.00 ➝ $300.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$275.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$301.00 ➝ $310.00
8/4/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$260.00 ➝ $270.00
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M16.15$0.93 per share122.70$6.16 per share18.47
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.38$2.36 per share9.53$13.18 per share1.71
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.60B3.63$16.32 per share15.78$71.07 per share3.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$0.42271.1048.42N/A6.52%8.26%6.45%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.41N/A18.001.32-3.96%8.13%3.99%N/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M$14.5017.7511.570.2320.45%33.97%13.02%N/A

Latest EWTX, JAZZ, ELAN, and CORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2692$0.34+$0.0708$0.11$1.31 billion$1.37 billion
8/3/2026Q2 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$6.18$5.71-$0.47$2.78$1.11 billion$1.21 billion
7/29/2026Q2 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.0243$0.36+$0.3357$0.36$221.15 million$256.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
2.86
2.77
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.58
2.05
1.10
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.69
1.78
1.58

Institutional Ownership

CompanyInstitutional Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%

Insider Ownership

CompanyInsider Ownership
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300108.10 million85.72 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.62 million493.93 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60108.60 million85.47 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89064.92 million62.25 millionOptionable

Recent News About These Companies

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
 |  zacks.comhttps://www.zacks.com/stock/news/2971708/unlocking-jazz-jazz-international-revenues-trends-surprises-and-prospects?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm_international_revenues-2971708
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
August 10 at 8:09 AM  |  reuters.comhttps://www.reuters.com/legal/litigation/jazz-bets-epilepsy-treatment-with-up-132-billion-deal-actio-2026-08-10/
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
August 10 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-acquire-actio-biosciences-expanding-rare-epilepsy-portfolio-302847060.html
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ
August 10 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-has-856-million-stake-in-jazz-pharmaceuticals-plc-jazz-2026-08-10/
Why Jazz Pharmaceuticals (JAZZ) is a top momentum stock for the long term
August 8 at 4:19 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-jazz-pharmaceuticals-jazz-is-a-top-momentum-stock-for-the-long-term/ar-AA29CiAZ
Jazz Pharmaceuticals plc 2026 Q2 - Results - Earnings Call Presentation
August 7 at 8:07 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4933562-jazz-pharmaceuticals-plc-2026-q2-results-earnings-call-presentation
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
August 7 at 10:51 AM  |  zacks.comhttps://www.zacks.com/stock/news/2970981/why-jazz-pharmaceuticals-jazz-is-a-top-momentum-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_momentum_score-2970981
Jazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication
August 7 at 7:17 AM  |  medscape.comM
What Does Jazz Pharmaceuticals (JAZZ) Raised Guidance Mean With FDA Decisions Ahead?
August 7 at 1:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-jazz-pharmaceuticals-jazz-raised-071422215.html
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Wells Fargo
August 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JAZZ/pressreleases/3665092/jazz-pharmaceuticals-jazz-receives-a-buy-from-wells-fargo/
JAZZ vs. TECH: Which Stock Is the Better Value Option?
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970173/jazz-vs-tech-which-stock-is-the-better-value-option?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-2970173
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares
August 6, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-jazz-insider-buying-and-selling-2026-08-06/
Needham & Company LLC Forecasts Strong Price Appreciation for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943790
Morgan Stanley Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $280.00
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943789
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 52-Week High on Analyst Upgrade
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943454
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943199
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,517,880.00 in Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-jazz-pharmaceuticals-nasdaqjazz-director-sells-151788000-in-stock-2026-08-05/
Jazz Pharmaceuticals' Re-Rating Story Has Legs
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930638-jazz-pharmaceuticals-re-rating-story-has-legs
Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DE
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jazz-pharmaceuticals-plc-jazz-stake-boosted-by-bank-of-america-corp-de-2026-08-05/
Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZ
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-acquires-53454-shares-of-jazz-pharmaceuticals-plc-jazz-2026-08-05/
Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 1-Year High Following Analyst Upgrade
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jazz-pharmaceuticals-nasdaqjazz-sets-new-1-year-high-following-analyst-upgrade-2026-08-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$113.78 +3.01 (+2.72%)
As of 01:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$22.50 +0.38 (+1.70%)
As of 01:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$43.36 -0.16 (-0.37%)
As of 01:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$257.54 +0.99 (+0.38%)
As of 01:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas